AstraZeneca’s “Buy” Rating Reaffirmed at Liberum Capital (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Liberum Capital in a report released on Thursday, AnalystRatings.NET reports. They currently have a GBX 4,600 ($75.81) price target on the stock. Liberum Capital’s price objective points to a potential upside of 18.74% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Berenberg Bank raised their price target on shares of AstraZeneca from GBX 3,420 ($56.36) to GBX 3,600 ($59.33) in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Separately, analysts at Leerink Swann upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Finally, analysts at Morgan Stanley upgraded shares of AstraZeneca to an “equal weight” rating in a research note to investors on Tuesday. Twelve investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have given a buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and a consensus target price of GBX 3,301.03 ($54.40).
Shares of AstraZeneca (LON:AZN) traded up 0.75% during mid-day trading on Thursday, hitting GBX 3874.0002. The stock had a trading volume of 2,673,391 shares. AstraZeneca has a 1-year low of GBX 2895.00 and a 1-year high of GBX 3886.50. The stock’s 50-day moving average is GBX 3568. and its 200-day moving average is GBX 3323.. The company’s market cap is £48.541 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.